Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

2
Corium Announces Issuance of Additional U.S. Patent Covering Corplex™ Donepezil Transdermal System for Alzheimer’s Disease

2018-07-11 globenewswire
MENLO PARK, Calif., July 11, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (NASDAQ:CORI), a commercial stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, announced today that the United States Patent and Trademark Office has issued a new key patent related to the company’s Corplex Donepezil Transdermal Delivery System (TDS), a once-weekly patch that delivers the most commonly prescribed medication for Alzheimer’s patients.
CORI AGRX MAYNF

13
Aequus and Corium Join Forces to Advance Anti-Nausea Transdermal Patch

2018-06-21 globenewswire
VANCOUVER, British Columbia, June 21, 2018 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today an expansion of its relationship with Corium International, Inc. (“Corium”) to include the Company’s long-acting transdermal patch, AQS1303, for the treatment of nausea and vomiting in pregnancy.
CORI AQSZF AQS

25
Corium Announces Issuance of Key U.S. Patent Covering Corplex™ Donepezil Transdermal System for Alzheimer’s Disease

2018-06-13 globenewswire
MENLO PARK, Calif., June 13, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (NASDAQ:CORI), a commercial stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, announced today that the United States Patent and Trademark Office (PTO) has issued a cornerstone patent related to the company’s Corplex Donepezil Transdermal Delivery System (TDS), a once-weekly patch that delivers the most commonly prescribed medication for Alzheimer’s patients.
CORI AGRX MAYNF

12
CORI / Corium International, Inc. S-3

2018-06-07 sec.gov
cori_Current_Folio_S3 Table of Contents
CORI

9
CORI / Corium International, Inc. 8-K (Current Report)

2018-05-23 sec.gov
cori_8K_20180514_ER UNITED STATES
CORI

25
TIM Participacoes (TSU) Enters Oversold Territory

2018-05-21 zacks
TIM Participacoes S.A. (TSU - Free Report) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors there is some hope when looking at TSU given that, according to its RSI reading of 25.23, it is now in oversold territory.
CORI AXDX AXDX] CSIQ COTY

24
Grupo Aeroportuario (OMAB) Sees Hammer Chart Pattern: Time to Buy?

2018-05-21 zacks
Grupo Aeroportuario del Centro Norte, S. A. B. de C. V. (OMAB - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because OMAB recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
CORI AXDX AXDX] CSIQ COTY

24
Why Earnings Season Could Be Great for Canadian Imperial Bank (CM)

2018-05-21 zacks
Investors are always looking for stocks that are poised to beat at earnings season Canadian Imperial Bank of Commerce (CM - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
CORI AXDX AXDX] CSIQ COTY

35
New Strong Sell Stocks for May 21st

2018-05-21 zacks
AZZ Inc. (AZZ - Free Report) is a provider of galvanizing services and highly engineered services. The Zacks Consensus Estimate for its current year earnings has been revised 6.5% downward over the last 30 days.
CORI AZZ BCML ESCA WISEX AXDX AXDX] CSIQ AXE COTY

25
Deere & Company (DE) Looks Good: Stock Adds 5.8% in Session

2018-05-21 zacks
Deere & Company (DE - Free Report) was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 6.3% in the past one-month time frame.
CORI TWI AXDX AXDX] CSIQ COTY

28
IBKR or E*TRADE: Which Investment Broker is a Better Pick?

2018-05-21 zacks
Benefits from a stabilizing economy and improving interest-rate scenario have well positioned the finance industry. The March-end quarter witnessed investors’ anxiety on uncertainty over the number of rate hikes on upbeat economic numbers and rising inflation, which pulled the benchmark 10-year Treasury bond yields down. This reversed the rally experienced by finance stocks since last September, to some extent.
CORI IBKR AXDX AXDX] CSIQ COTY

24
Are Options Traders Betting on a Big Move in JPMorgan (JPM) Stock?

2018-05-21 zacks
Investors in JPMorgan Chase & Co. (JPM - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jun 15, 2018 $45.00 Call had some of the highest implied volatility of all equity options today.
CORI AXDX AXDX] CSIQ COTY

25
Why Farmer Bros. (FARM) Could Be Positioned for a Slump

2018-05-21 zacks
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.
CORI NGVC AXDX AXDX] CSIQ COTY

25
Why TJX Companies (TJX) Might Surprise This Earnings Season

2018-05-21 zacks
Investors are always looking for stocks that are poised to beat at earnings season The TJX Companies, Inc. (TJX - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
TJX CORI AXDX AXDX] CSIQ COTY

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

8h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

9h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to CORI / Corium International, Inc. on message board site Silicon Investor.

Corixa [CRXA] - cancer vaccines CRIO: Corio, Inc.
Corinthians - Chapter 13 Corillian (CORI)
Corio (CRIO)
CUSIP: 21887L107